What is it about?
This is a post-hoc analysis of the pooled data of two pivotal trials on the effects of safinamide on motor fluctuations and on cardinal symptoms of PD in different subgroups of fluctuating patients, treated with levodopa alone or levodopa + other dopaminergic drugs, or with initial wearing-off.
Featured Image
Why is it important?
The findings of this post-hoc analysis suggest that safinamide can improve motor fluctuations and cardinal smptoms of PD even in patients with optimized dopaminergic therapy. Moreover, safinamide could be used either as first add-on to levodopa or as add-on in patients treated with levodopa and other dopaminergic therapies.
Read the Original
This page is a summary of: Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE, Journal of Parkinson s Disease, March 2016, IOS Press,
DOI: 10.3233/jpd-150700.
You can read the full text:
Contributors
The following have contributed to this page
